文献速递免疫规划卫生政策与健康促进

疫苗不良事件报告系统对过敏反应和吉兰-巴雷综合征的报告敏感性

The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
PubMed 文献 · Vaccine · 2020-10-07

该研究以VAERS安全审查数据为分子、VSD研究发病率为分母,估计VAERS对疫苗接种后过敏反应和吉兰-巴雷综合征的报告敏感性。结果显示,七种疫苗后过敏反应的敏感性为13%至76%,三种疫苗后GBS的敏感性为12%至64%,与既往对其他严重不良事件的估计相当。

要点

  • VAERS对过敏反应的报告敏感性因疫苗而异,范围为13%至76%。
  • VAERS对吉兰-巴雷综合征的报告敏感性范围为12%至64%。
  • VAERS敏感性与其他严重不良事件既往估计相当。

核心结论

  • 对于过敏反应和吉兰-巴雷综合征,VAERS的报告敏感性与既往检测疫苗接种后重要不良事件的估计相当。

研究设计与样本

  • 研究以VAERS安全审查数据为分子,以疫苗安全数据链(VSD)研究估计的接种后过敏反应和吉兰-巴雷综合征发病率作为分母,计算报告敏感性。

主要发现

  • VAERS对七种不同疫苗后过敏反应的报告敏感性范围为13%至76%。
  • VAERS对三种不同疫苗后吉兰-巴雷综合征的报告敏感性范围为12%至64%。
  • 过敏反应方面,VAERS捕获了肺炎球菌多糖疫苗后13%至27%的病例、流感疫苗后13%、水痘疫苗后21%、带状疱疹减毒活疫苗和四价人乳头瘤病毒(4vHPV)疫苗后各24%、麻腮风(MMR)联合疫苗后25%、2009年H1N1大流行流感灭活疫苗后76%的病例。
  • 吉兰-巴雷综合征方面,VAERS捕获了2012-13年季节性流感灭活疫苗后12%的病例、2009年H1N1大流行流感灭活疫苗后15%至55%的病例、4vHPV疫苗后64%的病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Underreporting is a limitation common to passive surveillance systems, including the Vaccine Adverse Event Reporting System (VAERS) that monitors the safety of U.S.-licensed vaccines. Nonetheless, previous reports demonstrate substantial case capture for clinically severe adverse events (AEs), including 47% of intussusception cases after rotavirus vaccine, and 68% of vaccine associated paralytic polio after oral polio vaccine. OBJECTIVES: To determine the sensitivity of VAERS in capturing AE reports of anaphylaxis and Guillain-Barré syndrome (GBS) following vaccination and whether this is consistent with previous estimates for other severe AEs. METHODS: We estimated VAERS reporting rates following vaccination for anaphylaxis and GBS. We used data from VAERS safety reviews as the numerator, and estimated incidence rates of anaphylaxis and GBS following vaccination from the Vaccine Safety Datalink (VSD) studies as the denominator. We defined reporting sensitivity as the VAERS reporting rate divided by the VSD incidence rate. Sensitivity was reported as either a single value, or a range if data were available from >1 study. RESULTS: VAERS sensitivity for capturing anaphylaxis after seven different vaccines ranged from 13 to 76%; sensitivity for capturing GBS after three different vaccines ranged from 12 to 64%. For anaphylaxis, VAERS captured 13-27% of cases after the pneumococcal polysaccharide vaccine, 13% of cases after influenza vaccine, 21% of cases after varicella vaccine, 24% of cases after both the live attenuated zoster and quadrivalent human papillomavirus (4vHPV) vaccines, 25% of cases after the combined measles, mumps and rubella (MMR) vaccine, and 76% of cases after the 2009 H1N1 inactivated pandemic influenza vaccine. For GBS, VAERS captured 12% of cases after the 2012-13 inactivated seasonal influenza vaccine, 15-55% of cases after the 2009 H1N1 inactivated pandemic influenza vaccine, and 64% of cases after 4vHPV vaccine. CONCLUSIONS: For anaphylaxis and GBS, VAERS sensitivity is comparable to previous estimates for detecting important AEs following vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Miller ER, McNeil MM, Moro PL, et al. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome. Vaccine. 2020. PMID: 33039207. doi:10.1016/j.vaccine.2020.09.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。